TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05250856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-201
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-201
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-201
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-201
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNP-201
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, (0.9% Sodium Chloride for IV infusion)
Study: NCT05180812

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ExoNet Tuned to Gravity Support
Description: This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExoNet Tuned to Gravity Support
Description: This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
Study: NCT06468358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1410
Description: anti-PD-1/TIM3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1410
Description: anti-PD-1/TIM3 bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB4330
Description: anti-claudin18.2/IL-10 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB4330
Description: anti-claudin18.2/IL-10 fusion protein
Study: NCT05439031

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Arrhythmia Radiotherapy
Description: Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
Study: NCT05192603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low FODMAP or SSRD
Description: The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low FODMAP or SSRD
Description: The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
Study: NCT06295055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge augmentation with semi-rigid shell barrier system
Description: The semi-rigid shell, fixed to the outside cortex by tacks, acts as a bone wall. Bone particles are placed in the gap and covered with the semi-resorbable covering membrane, serving as a barrier membrane.
Study: NCT04909151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (walking speed: 0.5km/h)
Description: Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (walking speed: 0.8km/h)
Description: Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (walking speed: 1.1km/h)
Description: Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
Study: NCT06239818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMt)
Description: Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
Study: NCT05134532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care
Study: NCT06211855

Intervention type: DIAGNOSTIC_TEST
Intervention: doppler assesment
Description: In all cases, the measurement, including UA PI and MCA PI, was measured with a 6-4 MHz convex transabdominal probe. All measurements were made by an obstetrician (Ş.D.) with 28 years of experience. Doppler measurements were collected from the proximal third of the MCA and the free-floating segment of the umbilical cord, ensuring that the angle of insonation was as close to zero as feasible and that fetal movements were absent
Study: NCT05228340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexor tenotomy
Description: Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
Study: NCT06403371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnsh
Description: Fluoride varnish was applied to the teeth surfaces before aligner therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline was applied to the teeth surfaces before aligner therapy
Study: NCT04792892

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months
Study: NCT06461754

Intervention type: OTHER
Intervention: Sonographic evaluation of diaphragm and lung
Description: While the patient in a semi-sitting position (20-40 degree), by ultrasound, the diaphragm thickness was measured in the zone of apposition, on the mid-axillary line among the 8th and 10th intercostal spaces, using a 7-10 MHz linear probe in (M) mode. at the end of expiration and at the end of inspiration by capturing nearly three images during spontaneous patient breathing. The average of three DTI measurements was calculated In lung ultrasound, 2-4 MHz convex ultrasound probe in (B) mode was employed. We implemented a modified LUSm in our investigation, which assessed four lung regions on each side.

Intervention type: OTHER
Intervention: Sonographic evaluation of diaphragm and lung
Description: While the patient in a semi-sitting position (20-40 degree), by ultrasound, the diaphragm thickness was measured in the zone of apposition, on the mid-axillary line among the 8th and 10th intercostal spaces, using a 7-10 MHz linear probe in (M) mode. at the end of expiration and at the end of inspiration by capturing nearly three images during spontaneous patient breathing. The average of three DTI measurements was calculated In lung ultrasound, 2-4 MHz convex ultrasound probe in (B) mode was employed. We implemented a modified LUSm in our investigation, which assessed four lung regions on each side.
Study: NCT04538105

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Saline Articular Nerve Branch Block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articular Branch Block (ABB)
Description: 0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
Study: NCT06197490

Intervention type: BIOLOGICAL
Intervention: Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation
Description: Collection of Uricuria, phosphaturie, calciuria, magnesuria, glycosuria, citraturia, oxaluria, before and after initiation of KAFTRIO

Intervention type: DRUG
Intervention: Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation
Description: Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
Study: NCT05992441

Intervention type: OTHER
Intervention: SCALE DEVELOPMENT STUDY
Description: The study to be carried out is a scale development study. The steps to be followed for the scale development study are as follows;~1. Creating an item pool by making use of the literature review on the subject,~2. Questioning the relevance of the prepared question pool to the subject to be measured with the Expert Evaluation Form by experts in the field,~3. Pilot application,~4. Switching to the main study after the pilot application,~5. After the factor and item analyzes, the final arrangements regarding the item and form of the scale will be completed.~As a result of this study, an awareness scale related to physiotherapy will be created for individuals with breast cancer.
Study: NCT05367999

Intervention type: DIAGNOSTIC_TEST
Intervention: initial Paroxysmal Event Profile
Description: The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
Study: NCT05731960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg IV dexamethasone provided immediately after spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg IV metoclopramide provided immediately after spinal anesthesia
Study: NCT05073094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol injected intravenously and added to cardioplegia solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
Study: NCT04822584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Product
Description: Baricitinib 4 mg/day orally for 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day orally for 36 weeks
Study: NCT06401187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bar overdenture
Description: use of bar attachments as retentive mean of denture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bar overdenture
Description: use of bar attachments as retentive mean of denture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bar overdenture
Description: use of bar attachments as retentive mean of denture
Study: NCT06032897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized music listening (IML)
Description: The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
Study: NCT04774003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
Description: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
Description: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
Study: NCT05514119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 160mg once daily orally for 12 weeks
Study: NCT05651256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
Study: NCT05510817

Intervention type: OTHER
Group type: OTHER
Intervention: Multiparametric assessment
Description: neuropsychological assessment, PRO measures, non-conventional MRI metrics
Study: NCT06476730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program
Description: 5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine medical care
Description: The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
Study: NCT04935632

Intervention type: BEHAVIORAL
Intervention: prevention training
Description: Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room

Intervention type: BEHAVIORAL
Intervention: prevention training
Description: Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room
Study: NCT05229900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-ALPV
Description: Given into the vein (IV; intravenously)
Study: NCT04926181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg once daily, for a 28 day cycle
Study: NCT05331079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 20 minutes of cryotherapy on the dominant knee with ice bags
Study: NCT04926181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: 480 mg given through intravenous infusion (IV) on day 1 of every 28-day treatment cycle and administered over a 60-minute infusion
Study: NCT04461041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Single oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
Study: NCT05665686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation training with device
Description: Relaxation training will be applied with the device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: An exercise application including home exercise programs will be performed for six weeks.
Study: NCT06044766

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical exatrction of impacted lower third molars
Description: Surgical exatrction of impacted lower third molars to verify the form of the root
Study: NCT06223763

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.

Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.

Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.

Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
Study: NCT04766333

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare Worker Focused Outreach
Description: This a focused outreach intervention strategy specifically designed for healthcare workers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Organization Led Outreach
Description: This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
Study: NCT04201600

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring System (CGMS)
Description: Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
Study: NCT04732000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
Study: NCT06126978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Therapy (Galileo Dela Interface)
Description: Vibration Therapy uses vibration as a physical tool during the treatment. It can be applied with different devices that transmit mechanical vibration throughout the whole or a part of the body. Focal Muscle Vibration (FMV) is a safe, well-tolerated and non-invasive technique, which may be an efficient intervention in reducing the upper extremity spasticity, whereas Whole Body Vibration (WBV) can provide proper somatosensory stimulation, and improve muscle strength and postural control in stroke patients (Oliveira et al., 2018).
Study: NCT04732000

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
Study: NCT06126978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror Therapy ( Mirror Box)
Description: Mirror Therapy is a structured, inexpensive, simple and patient-directed treatment. The principle of Mirror Therapy is the use of a mirror to create a reflective illusion of an affected limb, in order to trick the brain into thinking the movement has occurred without pain. It has shown to improve movements of the affected upper limb and the ability to carry out daily activities, in addition to reducing pain (Dhami et al., 2019).